Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories.

Haemophilia. 2019 May 20. doi: 10.1111/hae.13763. [Epub ahead of print]

PMID:
31106957
2.

The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.

Trossaert M, Graveleau J, Thiercelin-Legrand MF, Sigaud M, Guerrero F, Neel A, Fouassier M, Sailler L, Chauveau D, Ternisien C, Huart A, Gillet B, Hamidou M, Bene MC, Voisin S.

Haemophilia. 2019 May;25(3):527-534. doi: 10.1111/hae.13752. Epub 2019 May 2.

PMID:
31050100
3.

Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.

Dupont A, Soukaseum C, Cheptou M, Adam F, Nipoti T, Lourenco-Rodrigues MD, Legendre P, Proulle V, Rauch A, Kawecki C, Bryckaert M, Rosa JP, Paris C, Ternisien C, Boisseau P, Goudemand J, Borgel D, Lasne D, Maurice P, Lenting PJ, Denis CV, Susen S, Kauskot A.

Haematologica. 2019 Feb 28. pii: haematol.2018.206250. doi: 10.3324/haematol.2018.206250. [Epub ahead of print]

4.

Factor VIII assays in treated hemophilia A patients.

Lasne D, Pouplard C, Nougier C, Eschwege V, Le Cam Duchez V, Proulle V, Smahi M, Harzallah I, Voisin S, Toulon P, Sobas F, Galinat H, Flaujac C, Ternisien C, Jeanpierre E; groupe d'études de la biologie des maladies hémorragiques du Groupe français d'études de l'hémostase et la thrombose.

Ann Biol Clin (Paris). 2019 Feb 1;77(1):53-65. doi: 10.1684/abc.2019.1413.

PMID:
30799298
5.

Factor IX assays in treated hemophilia B patients.

Pouplard C, Jeanpierre E, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C; groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose.

Ann Biol Clin (Paris). 2019 Feb 1;77(1):41-52. doi: 10.1684/abc.2019.1414.

PMID:
30799297
6.

A new case of heterozygous variant of the GP1BB gene responsible for macrothrombocytopenia.

Babuty A, Boisseau P, Eveillard M, Ternisien C, Debord C, Sigaud M, Giraud M, Gillet B, Trossaert M, Béné MC, Fouassier M.

Br J Haematol. 2019 Jul;186(1):157-159. doi: 10.1111/bjh.15739. Epub 2019 Jan 4. No abstract available.

PMID:
30609015
7.

Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study ERHEA.

Desjonqueres A, Guillet B, Beurrier P, Pan-Petesch B, Ardillon L, Pineau-Vincent F, Sigaud M, Fouassier M, Ternisien C, Gillet B, Béné MC, Horvais V, Lienhart A, Trossaërt M.

Br J Haematol. 2019 May;185(4):764-767. doi: 10.1111/bjh.15606. Epub 2018 Oct 18. No abstract available.

PMID:
30338508
8.

Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature.

Boissier E, Genebrier S, Lakhal K, Nedelec-Gac F, Trossaërt M, Ternisien C, Gouin-Thibault I.

Thromb Haemost. 2018 Aug;118(8):1488-1490. doi: 10.1055/s-0038-1661391. Epub 2018 Jun 30. No abstract available.

PMID:
29960274
9.

Differential diagnosis of neonatal alloimmune thrombocytopenia: Type 2B von Willebrand disease.

Penel-Page M, Meunier S, Fretigny M, Le Quellec S, Boisseau P, Vinciguerra C, Ternisien C, Rugeri L.

Platelets. 2017 Dec;28(8):825-828. doi: 10.1080/09537104.2017.1293811. Epub 2017 Apr 24.

PMID:
28436749
10.

Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samples.

Caron C, Meley R, Le Cam Duchez V, Aillaud MF, Lavenu-Bombled C, Dutrillaux F, Flaujac C, Ryman A, Ternisien C, Lasne D, Galinat H, Pouplard C.

Int J Lab Hematol. 2017 Jun;39(3):279-285. doi: 10.1111/ijlh.12621. Epub 2017 Mar 20.

PMID:
28318109
11.

Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.

Espitia O, Ternisien C, Agard C, Boisseau P, Denis CV, Fouassier M.

Platelets. 2017 Jul;28(5):518-520. doi: 10.1080/09537104.2016.1246717. Epub 2016 Nov 25.

PMID:
27885890
12.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.

13.

Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF® -treated patients.

Pouplard C, Ternisien C, Desconclois C, Lasne D, Aillaud MF, Caron C.

Haemophilia. 2016 Mar;22(2):e101-e103. doi: 10.1111/hae.12867. Epub 2016 Jan 29. No abstract available.

PMID:
26822683
14.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.

PMID:
26791163
15.

Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome.

Halliez M, Fouassier M, Robillard N, Ternisien C, Sigaud M, Trossaert M, Bene MC.

Br J Haematol. 2015 Oct;171(2):290-292. doi: 10.1111/bjh.13391. Epub 2015 Mar 31. No abstract available.

PMID:
25823976
16.

Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience.

Ardillon L, Ternisien C, Fouassier M, Sigaud M, Lefrançois A, Pacault M, Ribeyrol O, Fressinaud E, Boisseau P, Trossaërt M.

Haemophilia. 2015 Sep;21(5):646-52. doi: 10.1111/hae.12653. Epub 2015 Mar 10.

PMID:
25753785
17.

Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.

de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hézard N, Trossaërt M.

Thromb Haemost. 2014 Oct;112(4):825-30. doi: 10.1160/TH14-02-0108. Epub 2014 Aug 7.

PMID:
25103956
18.

Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia.

Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, Biron C, Huisse MG, Ternisien C, Voisin S, Gruel Y, Pouplard C.

Br J Haematol. 2014 Sep;166(5):774-82. doi: 10.1111/bjh.12939. Epub 2014 May 12.

PMID:
24815503
19.

Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?

Pouplard C, Desconclois C, Sobas F, Aillaud MF, Ternisien C, Caron C.

Int J Lab Hematol. 2015 Feb;37(1):125-32. doi: 10.1111/ijlh.12253. Epub 2014 May 12.

PMID:
24815078
20.

Management of bleeding in severe factor V deficiency with a factor V inhibitor.

Ardillon L, Lefrançois A, Graveleau J, Fouassier M, Ternisien C, Sigaud M, Fretigny M, Archambeaud I, Trossaërt M.

Vox Sang. 2014 Jul;107(1):97-9. doi: 10.1111/vox.12134. Epub 2014 Feb 12.

PMID:
24517203
21.

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements.

Trossaert M, Lienhart A, Nougier C, Fretigny M, Sigaud M, Meunier S, Fouassier M, Ternisien C, Negrier C, Dargaud Y.

Haemophilia. 2014 Jul;20(4):550-8. doi: 10.1111/hae.12381. Epub 2014 Feb 12.

PMID:
24517184
22.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Legendre P, Navarrete AM, Rayes J, Casari C, Boisseau P, Ternisien C, Caron C, Fressinaud E, Goudemand J, Veyradier A, Denis CV, Lenting PJ, Christophe OD.

Blood. 2013 Mar 14;121(11):2135-43. doi: 10.1182/blood-2012-09-456038. Epub 2013 Jan 18.

23.

[Acquired hemophilia A. A monocentric retrospective study of 39 patients].

Graveleau J, Trossaërt M, Leux C, Masseau A, Ternisien C, Néel A, Fouassier M, Agard C, Sigaud M, Hamidou M.

Rev Med Interne. 2013 Jan;34(1):4-11. doi: 10.1016/j.revmed.2012.10.367. Epub 2012 Dec 14. French.

PMID:
23246283
24.

An unexpected transmission of von Willebrand disease type 3: the first case of maternal uniparental disomy 12.

Boisseau P, Giraud M, Ternisien C, Veyradier A, Fressinaud E, Lefrancois A, Bezieau S, Fouassier M.

Haematologica. 2011 Oct;96(10):1567-8. doi: 10.3324/haematol.2010.036897. Epub 2011 Jul 12. No abstract available.

25.

The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.

Pouplard C, Caron C, Aillaud MF, Ternisien C, Desconclois C, Dubanchet A, Sobas F.

Haemophilia. 2011 Sep;17(5):e958-62. doi: 10.1111/j.1365-2516.2011.02523.x. Epub 2011 Apr 4. Erratum in: Haemophilia. 2012 Jan;18(1):e42.

PMID:
21457408
26.

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.

Haemophilia. 2011 Nov;17(6):944-51. doi: 10.1111/j.1365-2516.2011.02499.x. Epub 2011 Mar 3.

PMID:
21371195
27.

Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity.

Trossaërt M, Boisseau P, Quemener A, Sigaud M, Fouassier M, Ternisien C, Lefrançois-Bettembourg A, Tesson C, Thomas C, Bezieau S.

J Thromb Haemost. 2011 Mar;9(3):524-30. doi: 10.1111/j.1538-7836.2010.04174.x.

28.

Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.

Toulon P, Abecassis L, Smahi M, Ternisien C.

Thromb Res. 2010 Dec;126(6):536-42. doi: 10.1016/j.thromres.2010.08.029. Epub 2010 Oct 14.

PMID:
20950840
29.

Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis.

Moles-Moreau MP, Ternisien C, Tanguy-Schmidt A, Boyer F, Gardembas M, Dib M, Ponthieux A, Guardiola P, Ifrah N, Hunault-Berger M.

Thromb Res. 2010 Nov;126(5):e394-6. doi: 10.1016/j.thromres.2010.08.002. Epub 2010 Sep 9. No abstract available.

PMID:
20825981
30.

Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease.

Trossaërt M, Ternisien C, Lefrancois A, Llopis L, Goudemand J, Sigaud M, Fouassier M, Caron C.

Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E25-9. doi: 10.1177/1076029610379848. Epub 2010 Aug 19.

PMID:
20724302
31.

[Antithrombin homozygous type II HBS deficiency (99Leu-Phe) associated with recurrent arterial thrombosis].

Durant C, Ternisien C, Connault J, Saint-Jean M, Planchon B.

Rev Med Interne. 2011 Mar;32(3):e29-31. doi: 10.1016/j.revmed.2009.08.023. Epub 2010 Jun 16. French.

PMID:
20557984
32.

[Appropriate laboratory investigation in women with menorrhagia].

de Raucourt E, Ternisien C.

J Gynecol Obstet Biol Reprod (Paris). 2008 Dec;37 Suppl 8:S317-28. doi: 10.1016/S0368-2315(08)74771-9. French.

33.

Reproducibility of blood tests of liver fibrosis in clinical practice.

Calès P, Veillon P, Konaté A, Mathieu E, Ternisien C, Chevailler A, Godon A, Gallois Y, Joubaud F, Hubert-Fouchard I, Oberti F, Réaud S, Hunault G, Mauriat F, Lunel-Fabiani F.

Clin Biochem. 2008 Jan;41(1-2):10-8. Epub 2007 Aug 24.

PMID:
17988658
34.

Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage.

Dib N, Quelin F, Ternisien C, Hanss M, Michalak S, De Mazancourt P, Rousselet MC, Calès P.

J Thromb Haemost. 2007 Oct;5(10):1999-2005.

35.

Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.

Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Régina S, Gruel Y.

J Thromb Haemost. 2007 Jul;5(7):1373-9. Epub 2007 Mar 14.

36.

Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene.

Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, de Maistre E, Regina S, Rugeri L, Ternisien C, Trichet C, Vergnes C, Aiach M, Alhenc-Gelas M.

Hum Mutat. 2006 Jun;27(6):600. Erratum in: Hum Mutat. 2006 Nov;27(11):1160.

PMID:
16705712
37.

A novel panel of blood markers to assess the degree of liver fibrosis.

Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F.

Hepatology. 2005 Dec;42(6):1373-81.

PMID:
16317693
38.

High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors.

de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C.

Am J Hematol. 2003 Nov;74(3):187-90.

39.

[A common mutation C677T in the 5,10-methyltetrahydrofolate reductase gene is associated to idiopathic deep venous thrombosis].

Berrut G, Ghali A, Quere I, Ternisien C, Gallois I, Roy PM, Marre M, Fressinaud P.

Rev Med Interne. 2003 Sep;24(9):569-76. French.

PMID:
12951177
40.

[Acquired von Willebrand disease and lymphoproliferative syndromes].

Hunault-Berger M, Rachieru P, Ternisien C, Jardel H, Zandecki M, Boasson M, Ifrah N.

Presse Med. 2001 Feb 10;30(5):209-12. French.

PMID:
12385052
41.

Prothrombin index is an indirect marker of severe liver fibrosis.

Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, Trossaert M, Rousselet MC, Chappard D, Calès P.

Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1133-41.

PMID:
12362105
42.

[Heparin induced thrombocytopenia: case report with acute thrombotic complications and literature review].

Plassat R, Cognet F, Ternisien C, Ménoret N, Dubus-Bausière V, Brunel P, Bontoux L, Bernat C, Richard I.

Ann Readapt Med Phys. 2002 May;45(5):216-23. Review. French.

PMID:
12020989
43.

[Anemia: a new cause of portal vein thrombosis? ].

Guichet C, Vuillemin E, Pilette C, Ternisien C, Calès P.

Gastroenterol Clin Biol. 2001 Aug-Sep;25(8-9):833-4. French. No abstract available.

44.
45.

[A rare disease but with a very high hemorrhagic risk: acquired hemophilia A].

Delisle V, Ternisien C, Beurrier P, Zandecki M.

Ann Biol Clin (Paris). 2000 Nov-Dec;58(6):741-4. French. No abstract available.

46.

[Essential thrombocythemia and cerebral ischemic accident: discussion of two cases].

Alecu C, Abraham P, Ternisien C, Enon B, Saumet JL.

J Mal Vasc. 1999 Oct;24(4):300-2. French.

PMID:
10582180
47.

Does venous microemboli detection add to the interpretation of D-dimer values following orthopedic surgery?

Abraham P, Ternisien C, Hubert L, Pidhorz L, Saumet JL.

Ultrasound Med Biol. 1999 May;25(4):637-40.

PMID:
10386740
48.

Diagnostic strategy in deep-vein thrombosis.

Roy PM, Barbeau C, Ternisien C, Leftheriotis G.

Lancet. 1998 May 23;351(9115):1588. No abstract available.

PMID:
10348672
49.

Diagnosis of venous thromboembolism.

Roy PM, Berrut G, Leftheriotis G, Ternisien C, Delhumeau A.

Lancet. 1999 Apr 24;353(9162):1446. No abstract available.

PMID:
10227254
50.

Protein tyrosine kinase activation is required for LPS and PMA induction of tissue factor mRNA in human blood monocytes.

Ternisien C, Ollivier V, Khechai F, Ramani M, Hakim J, de Prost D.

Thromb Haemost. 1995 Mar;73(3):413-20.

PMID:
7545319

Supplemental Content

Loading ...
Support Center